Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL6 | P41182 | 16/20 | 0.75 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.74 |
| ▸ | BCL6B | Q8N143 | 1/20 | 0.74 |
| ▸ | MELK | Q14680 | 1/20 | 0.56 |
| ▸ | NCOR2 | Q9Y618 | 5/20 | 0.56 |
| ▸ | ZAP70 | P43403 | 1/20 | 0.40 |
| ▸ | CAMK1D | Q8IU85 | 1/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.39 |
| ▸ | KARS1 | Q15046 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20284548 | 1.00 | BCL6 (0.75) | BCL6CHRM4BCL6BMELKNCOR2 | |
| SCHEMBL20284544 | 1.00 | BCL6 (0.75) | BCL6CHRM4BCL6BMELKNCOR2 | |
| SCHEMBL20284550 | 0.92 | BCL6 (0.85) | BCL6CHRM4BCL6BMELKNCOR2 | |
| SCHEMBL22932325 | 0.89 | BCL6 (0.86) | BCL6CHRM4BCL6BMELKNCOR2 | |
| SCHEMBL20267383 | 0.87 | BCL6 (0.74) | BCL6CHRM4BCL6BMELKNCOR2 | |
| SCHEMBL30713709 | 0.87 | BCL6 (0.85) | BCL6CHRM4BCL6BMELKNCOR2 | |
| SCHEMBL20284171 | 0.87 | BCL6 (0.83) | BCL6CHRM4BCL6BMELKNCOR2 | |
| SCHEMBL25228543 | 0.86 | BCL6 (0.82) | BCL6CHRM4BCL6BMELKNCOR2 | |
| SCHEMBL30486070 | 0.86 | BCL6 (0.82) | BCL6CHRM4BCL6BMELKNCOR2 | |
| SCHEMBL25223209 | 0.86 | BCL6 (0.79) | BCL6CHRM4BCL6BMELKNCOR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11001570-B2 | 6-amino-quinolinone compounds and derivatives as BCL6 inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-05-11 | — | — | US | disclosed |
| US-20200071297-A1 | NEW 6-AMINO-QUINOLINONE COMPOUNDS AND DERIVATIVES AS BCL6 INHIBITORS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2020-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200071297-A1 | NEW 6-AMINO-QUINOLINONE COMPOUNDS AND DERIVATIVES AS BCL6 INHIBITORS | BCL6, BCL6B, BCOR | BCL6 1/4885CHRM4 4574/4885BCL6B 2/4885 |
| US-11001570-B2 | 6-amino-quinolinone compounds and derivatives as BCL6 inhibitors | BCL6, BCL6B, BCOR | BCL6 1/4885CHRM4 4563/4885BCL6B 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.